Three technologies that could change the world

The Financial Times has consulted the experts in drug discovery and settled on three new technologies that promise to transform patient care in years to come. Most FierceBiotech readers are already familiar with RNAi, where a number of companies are competing to advance new therapies. GWAS is second on the list; individual genetic variations that highlight a person's risk of disease. Finally the FT lists IPSCs, the pluripotent stem cells that act like embryonic stem cells. Big challenges have yet to be met in the field, but the experts say the long-term potential here is amazing.

- read the article in the Financial Times

Suggested Articles

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.

The Big Pharma paid $134 million to enter into the two partnerships but then dropped the projects after Voyager completed research activities.